Stage
No active trials
Next date
None yet
Trials
3 active
6 in total · 5 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.”In the company’s words, NCT05372991 on ClinicalTrials.gov
- Tested for
- Myopia, Progressive
- Main trialPhase 1/2
- “This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers. CBT-009 has the active ingredient of atropine, which at low doses, has shown to be effective in slowing down myopic deterioration. Current atropine products are prone to degradation once the container is open to the air. ADS Pharmaceutical has developed a novel atropine formulation.”In the company’s words, NCT05372991 on ClinicalTrials.gov
- Other names
- Atropine
Other drugs for Myopia, Progressive
- AlleanceLaboratorios Sophia S.A de C.V. · Phase 3
- SHJ002Sunhawk Vision Biotech, Inc. · Phase 2
- IVMED-85 ophthalmiciVeena Delivery Systems, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 18 Jan 2023 | Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop | |
| Phase 3Authorised | not given | Low-dose AtropIne for Myopia control in children | |
| Phase 4Ended | not given | Postmarketing Parallel Randomized Clinical Trial to Determine the Efficacy and Safety of Atropine and DIMS Lenses in the Control of Myopia in a Pediatric Population | |
| Phase 3Authorised | not given | A phase III, randomized, double-masked, placebocontrolled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric subjects | |
| Phase 4Authorised | not given | Investigator led, double-masked, multicentre, randomized clinical trial for the comparison of atropine 0.5% versus atropine 0.05% eye drops for the prevention of myopia progression in Dutch children | |
| Phase 2Ended | not given | A randomized, double-blind, placebo-controlled dose-finding study of 0.05%, 0.025%, 0.01% and 0.005% atropine eye drops to inhibit myopia progression in children in a European population |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026